This site is intended for US healthcare professionals only.

Contact your XPOVIO® (selinexor) representative

Do you have questions or want to learn more about treating relapsed or refractory multiple myeloma (RRMM) or relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) with XPOVIO? Fill out the form below to connect with your XPOVIO representative. Please note that all fields are required.

Enter your contact information


XPOVIO® (selinexor) is a prescription medicine approved:

  • in combination with bortezomib and dexamethasone (XVd) to treat adult patients with multiple myeloma who have received at least one prior therapy.


Thrombocytopenia: XPOVIO can cause life-threatening
thrombocytopenia, potentially leading to hemorrhage.
Thrombocytopenia was reported in patients with multiple myeloma.

Thrombocytopenia is the leading cause of dosage modifications. Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Monitor patients for signs and symptoms of bleeding. Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.